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CObjective: When comparators’ prices decrease due to market compe-
tition and loss of exclusivity, the incremental clinical effectiveness re-
quired for a new technology to be cost-effective is expected to increase;
and/or the minimum price at which it will be funded will tend to de-
crease. This may be, however, either unattainable physiologically or
financially unviable for drug development. The objective of this study
is to provide an empirical basis for this discussion by estimating the
potential for price decreases to impact on the cost-effectiveness of new
therapies in hypertension. Methods: Cost-effectiveness at launch was
estimated for all antihypertensive drugs launched between 1998 and
2008 in the United Kingdom using hypothetical degrees of incremental
clinical effectiveness within the methodologic framework applied by
the UK National Institute for Health and Clinical Excellence. Incremen-
tal cost-effectiveness ratios were computed and compared with fund-
ing thresholds. In addition, the levels of incremental clinical effective-
ness required to achieve specific cost-effectiveness thresholds at given O
licy
al So
doi:10.1016/j.jval.2011.08.1736rices were estimated. Results: Significant price decreases were ob-
erved for existing drugs. This was shown to markedly affect cost-
ffectiveness of technologies entering the market. The required incre-
ental clinical effectiveness was in many cases greater than
hysiologically possible so, as a consequence, a number of products
ight not be available today if current methods of economic appraisal
ad been applied. Conclusions: We conclude that the definition of
ost-effectiveness thresholds is fundamental in promoting efficient in-
ovation. Our findings demonstrate that comparator price attrition has
he potential to put pressure in the pharmaceutical research model and
resents a challenge to new therapies being accepted for funding.
eywords: cost-effectiveness, health technology assessment, pharma-
eutical innovation, pharmaceutical price erosion, pharmaceutical re-
earch and development.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Policy context
Cost-effectiveness (CE) analysis is used to support funding de-
cisions for new drugs by estimating their clinical and economic
value. The purpose of CE thresholds is to achieve efficiency in
drug spending by requiring an acceptable or affordable cost per
unit of incremental effect compared to existing therapies. In
some disease areas, the prices of existing therapies fall over
time [1] due to market competition, entrance of generic drugs,
or negotiated price cuts. The implications of this price erosion
for new drugs entering the market are that they either need to
demonstrate greater incremental clinical effectiveness (IE) or be
developed for a lower price.
The factors underlying this are often external to the develop-
ment process and difficult to resolve. Development costs depend
greatly on the level of biologic uncertainty and the costs of meet-
ing regulatory requirements. At the same time, within a disease
* Address correspondence to: R. Refoios Camejo, IPC 4-1-06, HTA Po
Hill, Tadworth, Surrey, KT20 7NS, United Kingdom.
E-mail: rodrigo.refoioscamejo@pfizer.com
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.area, there is a physiologic limit to the incremental effect that a
new medicine can have [2]. This limit is composed of the efficacy
of the drug on its target mechanism and the number of mecha-
nisms involved in the disease process. Because the pharmaceuti-
cal industry assesses this at various stages of the research and
development (R&D) process, molecules that cannot meet these
limits of price or clinical effect will not be taken forward and in-
vestment will be stopped.
Research-based industries like the pharmaceutical industry
follow a dynamic process [3]. At a time where the average de-
velopment cost per viable drug is reported to have significantly
increased [4], continued innovation depends on achieving suf-
ficient return on investment to develop new compounds. Be-
cause the benefits of innovative products accrue not only to the
current generation but to all future generations [5,6], there is a
trade-off between increasing the welfare of current patients by
adopting only the most cost-effective technologies and increas-
ing the welfare of future patients by providing incentives for
future innovation through current pricing [7] and acceptance
- International Affairs, Walton Oaks, Dorking Road, Walton on the
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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382 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 8 1 – 3 8 8levels. This is now being recognized in newly proposed pricing
systems [8] and alternative frameworks that attempt to balance
he effects of price erosion and equity concerns across genera-
ions [9].
Theoretical framework
This study follows the framework proposed by Refoios Camejo et
al. [2] to discuss the dynamic effects of fixed CE constraints on drug
evelopment. They suggest the existence of a physiologically de-
ned clinical effectiveness ceiling for each disease area (ED max).
he maximum IE a new drug could attain over the existing stan-
ard care (Ec) if R&D resources were not finite is then defined by
IEd max  ED max  Ec (Eq. 1)
here subscript d refers to the new drug entering the market, c to
the comparator technology being used in the cost-effectiveness
assessment, and D to the disease area in question.
The drugs’ cost effectiveness can be represented by the incre-
ental cost effectiveness ratio (ICER), which is a ratio of the incre-
ental differences (on costs and benefits) between the new drug
nd any existent comparator; that is, ICER  Pd  Pc ⁄Ed  Ec. If a
xed CE threshold (L) is in place, a drug will be considered cost-
ffective if the given ratio is lower than L. In this way, the maxi-
um price premium allowed for a drug reaching ED max can be
omputed taking in consideration the price of the comparator (Pc).
hilst this price margin tends to diminish with time, the mini-
um possible launch price (Pd min) for a product to be considered
a viable investment tends to increase with inflation [2].
If Pd min is assumed to be exogenous, a minimum IE required
for approval (IEd min) can be calculated using L, Ec and Pc. When
Pd min  ED max  Ec * L  Pc or ED max  Ec 
Pd min  Pc
L
, i.e.,
ED max  Ec  IEd min, funding by the health system will most
likely be rejected. These considerations are increasingly part of the
portfolio selection criteria in the drug development process.
Therefore if this is the case, unless the R&D cost structure changes
significantly, no more R&D will be conducted for a particular dis-
ease area once it meets the above conditions.
The case of hypertension
We have selected hypertension to populate empirically the frame-
work proposed by Refoios Camejo et al. [2] because arguably
IEd max can be defined. Hypertension (classified as systolic blood
pressure 140 mm Hg or diastolic blood pressure 90 mm Hg) is a
risk factor for cardiovascular and renal conditions. For individuals
aged 40 to 70 years, an increment of 20 mm Hg in systolic blood
pressure doubles the risk of cardiovascular disease across the en-
tire blood pressure range [10]. The goal of antihypertensive ther-
apy is the reduction of cardiovascular and renal morbidity and
mortality. This may include both adoption of healthy lifestyles
and the use of pharmacologic treatment for the prevention and
reduction of high blood pressure. Since the first drug was approved
for the treatment of hypertension in 1946, several other pharma-
cologic treatments have proven clinical and economic outcomes
with an overall estimated benefit-to-cost ratio of at least six to one
[11]. Nevertheless, the economic burden of hypertension remains
substantial and cardiovascular disease is still one of the main
causes of death worldwide.
The study
Hoyle has found the reduction in the real price of drugs for hyper-
tension and coronary disease in the United Kingdom to be on av-
erage of 2.5% per year [1]. In this study we examined nominal
pharmaceutical prices of antihypertensive drugs in the United
Kingdom market during the past 10 years to detect if significantprice erosion, shown as a decrease in comparator drug prices, took
place. We simulated the IE of new entrants and estimated the
likelihood of funding approval if current CE decision rules had
been applied at time of launch. We also assessed the influence of
such price erosion on cost-effectiveness by calculating the size of
incremental decrease in systolic blood pressure that a new entrant
would need to demonstrate to be cost-effective according to cur-
rent criteria. In this article we propose an empirical basis for the
trade-offs between reimbursement rules, price erosion, and the
likelihood that new drug candidates will be developed based on
their ability to meet requirements for incremental effectiveness,
development costs, and price at launch.
Methods
We calculated the ICER at launch for new entrants to the hyper-
tension market between June 1998 and June 2008. Market and pric-
ing data on all antihypertensive drugs available in the United
Kingdom were used to identify comparators and drug prices. Be-
cause no historical head-to-head clinical trial data were available
for every drug at time of launch, different hypothetical values of IE
expressed as reduction in systolic blood pressure were assumed.
Using those, we estimated the likelihood of new entrants meeting
the £20,000 per quality-adjusted life year (QALY) cost-effective-
ness threshold as applied by the UK National Institute for Health
and Clinical Excellence [12]. We then estimated the IE required to
achieve acceptable CE standards at launch prices and compared it
with the physiological effectiveness limit set for hypertension.
Economic model
A cost-utility model was adapted to calculate the ICER in cost per
QALY gained for each new entrant to the hypertension market.
Reduction in systolic blood pressure was converted in the model
into cardiovascular events averted via a Framingham study-based
risk equation [13]. It has been suggested that Framingham-based
risk scores overestimate the patients risk of a cardiovascular event
[14] and that their use to predict clinical outcomes of drug inter-
ventions have not been validated [15]. Framingham-based risk
equations, however, have been widely applied in the technology
assessments this analysis intends to mimic. To simplify the anal-
ysis no adverse events or drug side effects were considered and
compliance was assumed to be 100% for all treatments adminis-
tered. The model followed the base case advocated by the UK Na-
tional Institute for Health and Clinical Excellence in their guide to
the methods of technology appraisal [12]. A brief description of the
economic model used can be found in Appendix 1 in Supplemental
Materials at: doi:10.1016/j.jval.2011.08.1736.
Data sources
Pharmaceuticals included in the study comprised all antihyper-
tensive drugs (i.e., main indication and primary use is hyperten-
sion) with reported sales in the UK market between June 1998 and
June 2008 as identified from the Intercontinental Medical Statistics
health database. The analysis was restricted to the same plan of
clinical management to guarantee comparability amongst all
drugs. Hence, retail pricing (price per pack) and market data (mar-
ket share in units sold) were retrieved for the drugs currently rec-
ommended for first, second, and third line treatment of hyperten-
sion in the United Kingdom [16]. Products were classified into
seven different therapeutic subclasses using the European Phar-
maceutical Market Research Association anatomical classification
system [17]: diuretics (C3), calcium antagonists plain (C8), angio-
tensin-converting enzyme inhibitors plain (C9A), angiotensin-
converting enzyme inhibitors combination (C9B), angiotensin II
antagonists plain (C9C), angiotensin II antagonists combination
(C9D), and other renin-angiotensin agents (C9X).
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Price per usual daily maintenance dose (p/MD) was the price indi-
cator employed in the analysis. This was computed for each prod-
uct using the list price of the highest selling presentation (strength
and pack) as given by Intercontinental Medical Statistics market
data and the dose suggested in the products’ most recent Sum-
mary of Product Characteristics. p/MD is seen as the most ade-
quate indicator: it reflects the approved dosages of the medicine in
the United Kingdom whilst taking into consideration the quantity
of active substance present in each preparation. Other studies
have used a market share weighted average price [1], but due to
the nature of the data available we selected a single presentation
to avoid eventual price discrepancies that could arise from market
discontinuation of particular presentations. Where included in
the analysis, generic products were grouped by molecule and con-
sidered as one product only with prices also being derived from
the highest selling presentation.
Selection of comparators
In line with current practice in the United Kingdom where the
cost-effectiveness of a new drug is estimated by comparing with
all drugs available for the same indication and target population,
we assumed market uniformity and full product substitutability.
Market leaders within the entire antihypertensive market (i.e.,
across all antihypertensive subclasses) were identified for each
year of the study period. These were selected as comparators for
all new entrants that year. All generic and nongeneric products
available were considered and selection was based on mid-year
(June) market share (units sold) data. See Table 1 for details on the
roducts used as comparators in each year of the analysis.
Analysis
Cost-effectiveness of new entrants was estimated by comparing
them to the identified comparator for their launch year. The clin-
ical effectiveness of comparators (Ec) was set at 9.10 mm Hg reduc-
tion in systolic blood pressure, as reported in a meta-analysis of
354 randomized clinical trials of antihypertensive drugs [18]. For
simulation purposes, Ec was assumed to remain constant during
the period studied. Three levels of hypothetical IE (5%, 10%, and
20% reduction on the comparator’s baseline systolic blood pres-
sure) were assumed and ICERs were calculated for each new en-
trant at all levels of IE. In the model, 5%, 10%, and 20% IE meant a
systolic blood pressure incremental decrease of 7.24 mm Hg, 14.49
mm Hg, and 28.98 mm Hg (137.66 mm Hg, 130.41 mm Hg, and
115.92 mm Hg final systolic blood pressure), respectively.
Subsequently we estimated the IEd min required to achieve the
20k/QALY, £30k/QALY and £40k/QALY thresholds. For this pur-
ose, launch prices of new entrants were assumed to represent
he minimum price required for each individual drug to be devel-
ped (Pd min)—information on the new entrants and particular
values used as Pd min can be found in Appendix 2 in Supplemental
aterials at: doi:10.1016/j.jval.2011.08.1736. The assumption that
he minimum price at which companies would launch their prod-
cts (Pd min) is exogenous and reflected fully in the launch price is
trong but a necessary one, because due to lack of clinical data
here was no possibility to differentiate new entrants according to
heir incremental benefit. This presumes that the pricing structure
oes not take comparator prices and, consequently, cost-effec-
iveness into consideration. Because R&D costs are expected to
ollow inflation Pd min would ceteris paribus expected to be higher
he later the product reaches the market.
The physiologically defined clinical effectiveness ceiling
ED max) was conservatively assumed to be a final systolic blood
ressure of 90 mm Hg, which corresponds to the upper limit of
ypotension [16]). As a result, the maximum incremental clinical
ffectiveness possible over a comparator (IEd max) was set to7.88%. Products requiring more than 37.88% IE to achieve CE stan-
ards were classified as impracticable. Products shown to be dom-
nant (less costly and more clinically effective than the compara-
or) for any degree of IE in the previous analysis was excluded from
his subanalysis and impracticable products were not considered
or statistical description (average and dispersion) of the sample.
Sensitivity analysis
A sensitivity analysis was performed on the comparator selection
method by comparing new entrants to products within their sub-
class only—aliskiren was the only product in its subclass (C9X
other renin-angiotensin agent) and was therefore excluded from
this. Also, an alternative price indicator was used as means of
sensitivity analysis: price per unit (p/Unit) with a unit correspond-
ing to the smallest portion in the package (e.g., pill or tablet) for
solid preparations or to 5 mL in the case of oral solutions. This was
conducted to test for potential discrepancies across molecules and
subclasses resulting from the method of computing the base case
price indicator (price/MD).
Results
Of the 152 antihypertension products available in the United King-
dom market from 1998 to 2008, 36 were first launched during that
period. Of these, four were new chemical entities and the remain-
ing were either generic or copy (molecule already released before
under a different product name) drugs, combination products,
new formulations or modified release compounds (Table 2).
Price of comparators
The price of the comparator for each subclass varied considerably
during the 10 years covered by the study in the majority of the sub-
classes. Major price changes appear to be related to the entrance of
generics. All subclasses appear to be affected by price erosion with
their average nominal price of comparators in 2008 being consider-
ably lower than the prices for the 1998 comparators (Fig. 1).
Cost-effectiveness and ICERs
In this analysis, pricing data on 36 products distributed across
seven different subclasses were considered. In the base case
analysis, ICERs were generated for the 36 new entrants at three
levels of hypothetical IE with comparators drawn across all sub-
classes and from all generic and nongeneric products (Fig. 2). A
constant level of clinical effectiveness was assumed for the
comparators throughout the study period; and the nominal
launch price of the new entrants and the nominal price of se-
lected comparators at the time of each individual launch were
used in the calculations. ICERs ranged from dominance to
£428,585/QALY. Six products (all introduced in the earlier period
when the market leader comparator was still nongeneric) were
dominant at all levels of IE. At the lower level of IE (5%), 14
products had ICERs greater than £100k/QALY, whereas at the
20% level of IE only one product exceeded this mark. Cost-effec-
tiveness improved with the hypothetical IE, but less than 42% of
drugs would be accepted at the 20% level of IE when applying a
£20k/QALY threshold.
Minimum incremental clinical effectiveness
Using a £20k/QALY threshold, IEd max; that is, the minimum IE
needed for a new drug to be accepted at the minimum viable
price from the developers perspective (Pd min), was on average a
21.34%  0.0991% or 30.93 mm Hg incremental reduction in sys-
tolic blood pressure over their comparator; that is, 40.03 mm Hg
total systolic blood pressure reduction (Table 3). Eleven prod-
ucts were classified as impracticable because the minimum IE
Table 1 – Products used as comparators for each subclass and across all subclasses in each period of the analysis.
Year Across all
subclasses
C3A diuretics C8A calcium
antagonists plain
C9A angiotensin-
converting enzyme
inhibitors plain
C9B angiotensin-converting
enzyme inhibitors
combination
C9C angiotensin
II antagonists
plain
C9D angiotensin II
antagonists
combination
C9X other renin-
angiotensin
agents
1998 ISTIN TAB 5MG 28 BUMETANIDE TAB
1MG 28
ISTIN TAB 5MG 28 INNOVACE TAB
10MG 28
ZESTEROTIC TAB
12.5MG20MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
1999 ISTIN TAB 5MG 28 FUROSEMIDE TAB
40MG 28
ISTIN TAB 5MG 28 INNOVACE TAB
10MG 28
ZESTEROTIC TAB
12.5MG20MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
2000 BENDROFLUMETH
TAB 2.5MG 28
BENDROFLUMETH
TAB 2.5MG 28
ISTIN TAB 5MG 28 ZESTRIL TAB 10MG
28
ZESTEROTIC TAB
12.5MG20MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
2001 BENDROFLUMETH
TAB 2.5MG 28
BENDROFLUMETH
TAB 2.5MG 28
ISTIN TAB 5MG 28 ZESTRIL TAB 10MG
28
ZESTEROTIC TAB
12.5MG20MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
2002 BENDROFLUMETH
TAB 2.5MG 28
BENDROFLUMETH
TAB 2.5MG 28
ISTIN TAB 5MG 28 ZESTRIL TAB 10MG
28
ZESTEROTIC TAB
12.5MG20MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
2003 BENDROFLUMETH
TAB 2.5MG 28
BENDROFLUMETH
TAB 2.5MG 28
ISTIN TAB 5MG 28 LISINOPRIL TAB
20MG 28
ZESTEROTIC TAB
12.5MG20MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
2004 BENDROFLUMETH
TAB 2.5MG 28
BENDROFLUMETH
TAB 2.5MG 28
AMLODIPINE TAB
5MG 28
LISINOPRIL TAB
20MG 28
ZESTEROTIC TAB
12.5MG20MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
2005 BENDROFLUMETH
TAB 2.5MG 28
BENDROFLUMETH
TAB 2.5MG 28
AMLODIPINE TAB
5MG 28
RAMIPRIL TAB
10MG 28
ZESTEROTIC TAB
12.5MG20MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
2006 BENDROFLUMETH
TAB 2.5MG 28
BENDROFLUMETH
TAB 2.5MG 28
AMLODIPINE TAB
5MG 28
RAMIPRIL TAB
10MG 28
ZESTEROTIC TAB
12.5MG20MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
2007 BENDROFLUMETH
TAB 2.5MG 28
BENDROFLUMETH
TAB 2.5MG 28
AMLODIPINE TAB
5MG 28
RAMIPRIL TAB
10MG 28
LISINOPRIL/HYDROCH TAB
12.5MG10MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
NA
2008 BENDROFLUMETH
TAB 2.5 mg 28
BENDROFLUMETH
TAB 2.5MG 28
AMLODIPINE TAB
5MG 28
RAMIPRIL TAB
10MG 28
LISINOPRIL/HYDROCH TAB
12.5MG10MG 28
COZAAR FC TAB
50MG 28
COZAAR COMP FC TAB
12.5MG50MG 28
RASILEZ FC TAB
150MG 28
Note: Products were classified into seven different therapeutic subclasses using the European Pharmaceutical Market Research Association anatomical classification system.
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385V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 8 1 – 3 8 8needed for a new drug to meet the threshold was greater than
what was physiologically possible; that is, IEd min was greater
than IEd max. When the threshold was increased to £30k/QALY
and £40k/QALY the number of impracticable products was re-
duced to three and two while the average IEd max was 18.82% 
.0975% and 14.55%  0.0791%, respectively.
Sensitivity analysis
When comparators were restricted to the new entrants’ own sub-
class, 35 products distributed in six different subclasses were con-
sidered. The majority (n26) of the products did not have a generic
comparator at the time of entry in their subclass and the percent-
age of products meeting the ICER acceptability criteria was con-
siderably higher than in the base case analysis for all levels of IE.
Three products were classified as impracticable with greater
IEd min than IEd min. When averaged across products in all sub-
lasses IEd max ranged from 9.60% (14.00 mm Hg incremental re-
uction in systolic blood pressure) to 13.97% (20.24 mm Hg incre-
ental reduction in systolic blood pressure) for the three
hresholds studied (Table 2).
Drug prices were calculated using an alternative method and
ll analysis were reconducted with a different price indicator (p/
nit). Individual changes in ICER values were identified but no
ajor variation on acceptability rates was found when comparing
he results with the base case.
Table 2 – Overview of new entrants by subclass, United Kin
Class New
entrant
N
mol
C3A diuretics 2
C8A calcium antagonist plain 17
C9A ACE inhibitors plain 6
C9B ACE inhibitors combination 2
C9C angiotensin II antagonists plain 3
C9D angiotensin II antagonists combination 5
C9X other renin-angiotensin agent 1
ACE, angiotensin-converting enzyme.
* Molecule already released before under a different product name.
Fig. 1 – Price of comparators (£/MD) for each subclass and ac
maintenance dose (p/MD) which is computed using the list p
given by IMS market data and the dose suggested in the productDiscussion
Hypertension is historically one of the largest and most impor-
tant markets for the pharmaceutical industry. In the period
analysed in this study, the majority of new entrants were either
noninnovative generic products or new formulations of previ-
ously released molecules. Only four of the 36 products identified
correspond to new molecules, which reflects the mature stage
of this disease area. Although no data on R&D investment on
hypertension was collected, one could argue the R&D effort was
put elsewhere during the past two decades despite the fact that
clinical need is still considerable. The low R&D output may be
related with the principle that the majority of all known phar-
macologically controllable risk factors are already completely or
partially dealt with. In this case, improvements in the hyper-
tension outcomes can only be attained through adjustments in
disease management or through new drug treatment combina-
tions that might assist in adherence. It is important to assess
the degree to which pricing patterns and the use of CE decision
rules play a role in this scenario, which is what we tried to
achieve with this study.
In line with Hoyle’s analysis [1], we detected a significant de-
crease in the nominal prices of antihypertensive drugs available in
the market from 1998–2008. We also noted a progressive price
erosion of the nominal price of comparators that would be used in
m 1998–2008.
Generic or
copy*
Combination Modified release or
new formulation
  2
6  11
6  
1 1 
  
 5 
  
subclasses. Note: Price indicator used is price per
of the highest selling presentation (strength and pack) asgdo
ew
ecule




3

1ross
rices’ most recent Summary of Product Characteristics (SPC).
386 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 8 1 – 3 8 8cost-effectiveness analysis of new antihypertensive drugs. This
influences significantly the degree of IE necessary to bring ICERs of
new products to an acceptable range. As a consequence, a number
of drugs might not be available today if they were launched at the
same price and current requirements of economic assessment
were in place at the time of their launch. Because the minimum IE
needed for a drug to be approved is often above what is physiolog-
ically possible, this would happen irrespectively of the IE drugs
demonstrated in clinical trials.
It should be noted that this study looks at prices as given and is
a hypothetical exercise not assessing if particular drugs should be
accepted or not. Due to the remit of the work and perspective
taken, the sensitivity analysis prioritized the review of uncertainty
Fig. 2 – ICERs at time of launch assuming three levels (5. 10.
Note: The figure shows the ICERs at time of launch of all new
entrants in the market was not constant, the number of dat
entrant, three ICERs relative to each of the different levels of
launch prices, the clinical benefit derived from reducing the
and 20% is used in the calculation of the ICERs.
Table 3 – Average incremental clinical effectiveness requir
(QALY) gained thresholds.
Primar
Comparator £20k/QAL
All subclasses (base case)
Average IE [SD] 21.34% [0.09
Impracticable (n) 11
Within-subclass (sensitivity analysis)
Average IE [SD] 13.97% [0.09
Impracticable (n) 3
Note: The incremental clinical effectiveness (IE) required on average
(£20k/QALY, £30k/QALY, £40k/QALY) is presented here together wi
analysis using a comparator selected across all subclasses, whilst in
new entrant. The number of impracticable drugs (i.e., products for wh
Products shown to be dominant for any degree of IE were excluded f
statistical description (average and dispersion).originated from the degree of IE, method of selecting comparators
and price indicators used in model. Other variables may have been
overlooked and these results should not be used for other pur-
poses than the discussion set herewith. The major limitation of
the study is the lack of clinical data on the new entrants and on the
evolution of the level the standard care throughout the study pe-
riod. This results in a nonperfect fit to the framework proposed by
Refoios Camejo et al. [2]. The objective of this analysis to assess the
effects of price erosion on cost-effectiveness and to shed light on
the levels of incremental benefit needed for new drugs to achieve
funding can still be achieved by recurring to hypothetical levels of
IE. Also, the value of innovation in pharmaceuticals is often de-
rived from more unobvious benefits that may not necessarily be
) of hypothetical incremental clinical effectiveness (IE).
ducts entering the market. Since the number of new
nts for each year varies across the years. For each new
re represented. Hence, in addition to the new entrants’
parators’ baseline systolic blood pressure (sBP) in 5%, 10%
achieve specific cost per quality-adjusted life years
alysis
£30k/QALY £40k/QALY
18.82% [0.0975] 14.55% [0.0791]
3 2
13.03% [0.1026] 9.60% [0.0737]
1 1
ew entrants to achieve particular cost per QALY gained thresholds
e respective standard deviation (SD). Base case corresponds to an
nsitivity analysis comparators were restricted to the subclass of the
e IE needed was greater than maximum IE possible) is also shown.
his subanalysis and impracticable products were not considered for20%
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387V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 8 1 – 3 8 8captured in randomized clinical trials. These are often overlooked
and not included explicitly in the funding decision analysis. In our
study the benefit of new drugs was represented by IE, which was
driven by the reduction in systolic blood pressure only.
Clinical management of hypertension is conducted by inter-
changeably using various subclasses of drugs according to patients’
characteristics and preferences [16]. This was accounted for by re-
stricting the products analyzed to the same plan (up to third line) of
the clinical management protocol currently in place in the United
Kingdom [16]. Thus, for the purposes of this study the drugs analyzed
can be perceived as clinically comparable. New technologies are used
mainly in patients for whom existing drugs are not effective or well
tolerated. Unarguably, an economic model accounting for all sub-
group characteristics would be more appropriate and would allow to
include the possibility of the new drug to be accepted for use in par-
ticular types of patients. This additional complexity would not nec-
essarily change the essence of the conclusions. If the indication was
to be restricted to a smaller subpopulation, sales volume would be
smaller and Pd min would need to be considerably higher to still war-
ant a positive net present value [2]. It could be argued that the need
or a higher Pd min might be accommodated by orphan drug legisla-
ion in place. This would be highly controversial [19–21], and could
ot be applied to all subpopulations across all diseases.
It seems unambiguous that price erosion was already in place in
he hypertension market early on in the period studied. Price of com-
arators then fell considerably mainly due to the introduction of ge-
eric products and the picture of price erosion would be more severe
f real prices were considered instead of nominal prices. Yearly per-
entage variation in the price of comparators was often uniform
cross subclasses; however, price variation does not appear to nec-
ssarily follow a particular pattern. It is also apparent that the timing
f the appraisal influences cost-effectiveness estimations and those
ecisions may differ if they are to be taken at different points in time.
ecause developers assess the comparative value of the product
arly in the development process, random fluctuation in comparator
rices increases uncertainty in market signals and market response
ay become more difficult to predict.
From a clinical perspective, price erosion may bring a positive
ffect on compliance among patients due to lower out-of-pocket pay-
ents. As demonstrated, it may also result in having fewer mole-
ules in the market and fewer clinical options for disease manage-
ent. Normally, the value of having such alternatives would not be
xplicitly captured in cost-effectiveness analyses, but their unavail-
bility would have an immediate opportunity cost [22]. This is also
xpected to affect the development of subsequent products if it is
ccepted that pharmaceutical innovation is path dependent. If a dy-
amic perspective is to be taken, any expected benefits occurring
rom future spin-off innovation should be measured against IE po-
ential and included in the CE equation. Product lifecycle ICERs con-
idering “future incident cohorts” could be helpful in dealing with
his issue, and reduce the inequity across generations potentially
reated by a static cost-effectiveness framework [9].
If launch prices do reflect development costs, our results also
uggest that the current CE framework indicates that innovation
n a specific disease may become unattainable or too expensive as
oon as price erosion occurs. There will always be a point where
nnovation is not efficient or affordable at which investment
hould be naturally directed to other therapeutic areas. Price ero-
ion can be seen as a helpful mechanism to identifying that point.
owever, it should not be the only one and the main challenge
emains in assessing if and how the ideal point of innovation dif-
ers across therapeutic areas. Society’s valuation of meeting a clin-
cal need varies across disease areas and R&D intensity is also not
xpected to be constant. Hence, the validity of this decision will
epend on the degree to which cost-effectiveness threshold re-
ects the clinical need and the potential for innovation of the par-
icular therapeutic area in study. Being key drivers of the researchodel, these disease-specific factors should be explicitly included
n the funding decision rules because they are now included in the
evelopers’ investment decisions.
The methods for technology assessment are fundamental in
romoting efficient innovation and funding criteria, but it is argu-
ble that a single general CE threshold is sufficient and desirable
rom a dynamic perspective where ED max is considered. The
ewly proposed revision of the UK pricing system suggests this
ay now start to be taken explicitly into consideration [8]. It re-
ains unclear how and to what extent the dynamic aspect of drug
evelopment will be part of the funding decision criteria, though.
f not done successfully, research priorities may be shifted to ther-
peutic areas where the price of currently available compounds
oes not necessarily require a large IEd min. This may ultimately
result in market failure in some mature or quasimature therapeu-
tic areas where clinical need is still considerable.
The applicability of these results to other therapeutic areas and
other countries is not guaranteed, especially as pharmaceutical de-
velopment is a global matter and pricing structures and funding sys-
tems may differ from the ones explored in this article. Further re-
search is needed to assess particular market characteristics that may
influence significantly the ability of the pharmaceutical industry to
introduce innovative compounds in maturing disease areas. Similar
analyses focusing on different therapeutic areas with alternative
data sources and including other countries should offer further un-
derstanding of the pharmaceutical pricing structure after market in-
troduction and its effects on cost-effectiveness of new drugs.
Conclusions
Price erosion is a natural process of the pharmaceutical markets re-
flecting the nature of market competition. Our findings demonstrate
it has the potential to put pressure in the current pharmaceutical
R&D model by raising the hurdle to new molecules in demonstrating
sufficient IE to be allowed launch. In disease areas where clinical
need still exists this may come into conflict with the requirement to
ensure sufficient incentive for future innovation. Funding criteria is
fundamental in promoting efficient innovation and should reflect
pharmaceutical development features and the specific disease-area
innovation potential. It should also explicitly consider the inter-gen-
erational trade-off between the current benefits of more cost-effec-
tive technologies against the future costs of less investment in re-
search. Otherwise, price erosion may perversely drive research to be
directed to therapeutic areas where incremental clinical effective-
ness requirements are lower and easier to achieve irrespectively of
clinical need and potential for future innovation.
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